Adolescents and Young Adults
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Adolescents and Young Adults
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
This 1-hour, on-demand session from the 2022 ASAM State of the Art Course explores distinct topics related to adolescent substance use and addiction, including adolescent e-cigarette addiction and clinically relevant substance-related findings from the Adolescent Brain Cognitive Development (ABCD) Study.
Youth drug abuse is a public health concern, with at least 1-in-8 teenagers abusing an illicit substance in the last year. This 1-hour, on-demand session from the 2022 ASAM State of the Art Course explores distinct topics related to adolescent substance use and addiction, including adolescent e-cigarette addiction and clinically relevant substance-related findings from the Adolescent Brain Cognitive Development (ABCD) Study. Following each presentation, presenters answer audience questions.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- ABCD Study
This session will review the most recent substance-related findings from the Adolescent Brain Cognitive Development (ABCD) Study. The presenter will give an overview of the landmark study and cover the most current and clinically-relevant ABCD findings, including: (1) the effects of prenatal substance exposure on child development and (2) the consequences of preadolescent alcohol experimentation on health outcomes. Providers will leave with tangible information to share with their patients, and researchers will better understand what data are available for further analysis to inform substance-use clinical practice.
- Youth E-cigarette Usage Pandemic: How to manage e-cigarette addiction
This session will provide insight into nicotine addiction, specifically its challenges in cessation that come from resulting neuroanatomical changes. Further, the session will provide insight into how current management of nicotine addiction that result from combustible cigarettes can assist patients struggling with electronic cigarette addiction management, while identifying current gaps that necessitate ongoing research around electronic cigarette addictions. Finally, the session will review real-world clinical cases that highlight a care strategy to assist patients in their electronic cigarette addiction.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
|ASAM Learner Type||Rate|
Refunds & Cancellations
Registration Deadline: 10/1/2025
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
Frank J. Vocci, PhD (Moderator)
President and Senior Research Scientist, Friends Research Institute, Inc.
Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA where he reviewed applications for marketing of analgesic medications and also participated in domestic and international drug scheduling issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse and became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997. During his tenure at NIDA, four addiction drug products that were developed or co-developed by his division were approved by the FDA and another was approved following his retirement from NIH in 2010. Following his retirement from NIDA in December 2008 Dr. Vocci became President of Friends Research Institute in January 2009. He has published over 100 articles and book chapters and has participated as a grant reviewer for the Department of Defense, the Veterans Administration, the National Institutes of Health, the Brain Research Foundation, and the Peter Dodge Foundation, He is a Past-President of the College on Problems of Drug Dependence and a co-editor of the Journal of Addiction Medicine.
Does Disclose - 1. Takeda Pharmaceutical Co. - Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received), 2. Nirsum Labs - Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received), 3. Revive Therapeutics - Consultant/Advisory Board,Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received)
Lindsay Squeglia, PhD
Medical University of South Carolina
Dr. Lindsay Squeglia is an Associate Professor and licensed clinical psychologist at the Medical University of South Carolina (MUSC) in the Department of Psychiatry and Behavioral Sciences. She is the co-Director of the MUSC Youth Collaborative, and her National Institutes of Health-supported research focuses on: (1) understanding the effects of alcohol and cannabis use on adolescent and young adult brain development and (2) using neuroscience to improve prevention and treatment of adolescent substance use disorders. She co-leads MUSC's site for the nationwide Adolescent Brain Cognitive Development Study (ABCD) and is on the ABCD Steering Committee, ABCD Novel Technology Workgroup, and ABCD Community Engagement and Dissemination Workgroup. She has a strong interest in community outreach and education efforts and leads the MUSC High School Teen Science Ambassador Program, providing high school students with a three phase internship experience in academic clinical research. Dr. Squeglia is originally from South Carolina and grew up in the Charleston area. She received a Bachelor’s degree in Experimental Psychology at the University of South Carolina and a PhD in Clinical Psychology from the San Diego State University/University of California San Diego (UCSD). She completed her clinical internship in neuropsychology at the University of California Los Angeles and her postdoctoral fellowship in neuroimaging at UCSD. In 2021, she received a Fulbright Scholar Award to build a cross-national collaboration between the US and Australia to improve health outcomes globally for youth struggling with problematic substance use.
No Relevant Financial Disclosures
Panagis Galiatsatos, MD, MHS
Johns Hopkins School of Medicine
Panagis Galiatsatos, MD, MHS is an Assistant Professor at the Johns Hopkins School of Medicine. He is the co-chair of the Johns Hopkins Health Equity Steering Committee and the co-director and co-founder of Medicine for the Greater Good, a novel medical initiative impacting over 10,000 Baltimore City lives in regards to health and wellness while at the same time creating physician-citizens. He has published over 60 research articles, with a focus on health equity, community engagement, and contextual-level variables impact on health outcomes. He is also a co-author of a book series, "Building Health Communities", where a review in JAMA discusses "this book literally has the potential to save lives". He has a TED talk discussing the need for healthcare to engage with the local community for health equitable outcomes. He completed his undergraduate studies at Temple University, his medical school at the University of Maryland School of Medicine, his internal medicine training at the Johns Hopkins School of Medicine, his critical care medicine training at the National Institutes of Health, and his pulmonary training at the Johns Hopkins School of Medicine. During the pandemic, Dr. Galiatsatos and colleagues coordinate community engagement to assure all populations were able to access COVID-19 updates and resources in an effort to assure compliance with public health requests. His clinical responsibilities center on critical care services in adult populations, Director of the Tobacco Treatment Clinic at Johns Hopkins Medicine, Associate Director of The Hereditary Hemorrhagic Telangiectasia Center of Clinical Excellence, and Physician in The Obstructive Lung Disease Group at Johns Hopkins Medicine and in the post-COVID-19 acute clinic.
No Relevant Financial Disclosures
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
|Access Date||Quiz Result||Score||Actions|